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Background. The pathogenesis underlying the increased predisposition to the development of basal cell carcinomas (BCCs) in
the context of Gorlin-Goltz syndrome is linked to molecular mechanisms that differ from sporadic BCCs. Patients with Gorlin
syndrome tend to develop multiple BCCs at an early age and present with tumors of non-sun-exposed skin. The aim of this study
was to compare the proteomic profile of cultured fibroblast and fibroblast conditioned culture media of PTCH1+ and nonmutated
fibroblasts. Results. Proteomic analysis was performed using Surface-Enhanced Laser Desorption/Ionization Time-of-Flight mass
spectrometry in PTCH1+ fibroblast conditioned media isolated from not affected sun-protected skin areas of Gorlin patients and
from healthy subjects. 12 protein cluster peaks, >5 kDa, had significant differences in their peak intensities between PTCH1+ and
PTCH1− subject groups. We detected a strongly MMP1 overexpression in PTCH1+ fibroblasts obtained from NBCCS patients
with respect to healthy donors. Conclusion. Protein profiles in the fibroblast conditioned media revealed statistically significant
differences between two different types (missense versus nonsense) of PTCH1 mutations. These differences could be useful as
signatures to identify PTCH1 gene carriers at high risk for the development of NBCCS-associated malignancies and to develop
novel experimental molecular tailored therapies based on these druggable targets.
1. Introduction
Patients with germ-line mutations in tumor suppressor genes
represent an intriguing heredofamilial model of cancer sus-
ceptibility and genotype-phenotype correlation [1]. PTCH1
mutations lead to complex syndromes such as the Gorlin
syndrome (GS) also named nevoid basal cell carcinoma
syndrome (NBCCS, OMIM #109400). GS is a rare autosomal
dominant disorder characterized by striking predisposition
to the development of basal cell carcinomas (BCCs) (up to
hundreds) [2], keratocystic odontogenic tumors (KOCTs)
of the jaws, palmar and/or plantar pits, and developmental
defects. A variety of other benign ormalignant tumors can be
found in association with these developmental defects, that
is, ovarian fibroma, medulloblastoma, rhabdomyosarcomas
cardiac fibromas, and ameloblastoma.
In this hereditary setting, the genotype-phenotype cor-
relation is not always present: gene carriers and family
members sharing the same PTCH1 germ line mutation have
a variable phenotype [3]. However, in contrast to sporadic
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BCCs, all BCCs found in GS are observed in both sun-
protected and sun-exposed areas.Moreover, there is scientific
evidence for the distinct pathogenesis and clinical behaviour
of those cutaneous neoplasms in the diverse [4], as well as
for the increased expression of matrix metalloproteinase-3 in
cultured fibroblasts and BCCs in GS [5].
A systemic tailored therapy has been introduced in clini-
cal practice, for GS patients with multiple BCCs that cannot
undergo surgery [6], showing satisfying rates of objective
response. Unfortunately, the effective response is limited by
drug resistance [7].The latter might be due to the occurrence
of additional mutations that, bypassing the specific target
mechanisms of inhibition, lead to tumor cell proliferation;
an alternative is represented by posttranslational changes
that affect proteins, codified by genes implied in the Sonic
Hedgehog Homolog (SHH) pathway.
Among themodern technologies proteomics can be emp-
loyed in the discovery and identification of protein profi-
les possibly related to different sporadic and hereditary phe-
notypes. Surface-Enhanced Laser Desorption/Ionization
Time-of-FlightMass Spectrometry (SELDI-ToFMS) is a pro-
teomic tool for differential expression profiling which per-
mits to detect a large number of low-molecular weight pro-
teins (<20 kDa) [8–10]. Selectively retained proteins, from
ProteinChip chromatographic surfaces, are directly analy-
zed by laser desorption ionization resulting in a mass spe-
ctrum consisting of the mass to charge (m/z) ratio and
intensities of the bound peptide/protein [11].
In this study, we postulated that fibroblasts in patients
with GS may possess characteristics determining BCC devel-
opment being responsible for the production of proteins
(cytokines and growth factors) promoting the basaloid prolif-
eration. To validate the existence of specific protein patterns
in culture media of PTCH1mutated fibroblasts, we compared
the proteomic expression of PTCH1+ fibroblast conditioned
culture media to that of healthy control fibroblasts under
the same conditions. We also investigated patients with
different subtypes of germ-line PTCH1 mutations, through
the comparison of both genetic and proteomic profiles.
2. Materials and Methods
2.1. Ethics Statement. This study was approved by the Ethical
Committee of the University Hospital of Modena, Italy, and
was conducted after informed written consent of NBCCS
patients.
2.2. Patients. Patients were characterized for their phe-
notypic aspects as studied through clinical examination.
PTCH1− patients included Wilde Type healthy controls and
PTCH1 not mutated NBCCS patients, PTCH1+ patients (ger-
mline mutated patients). The definition of “aggressive” phe-
notype is defined by a large number of big diameter BCCs
and/or OKCTs and other NBCCS clinical criteria.
Biological samples were collected from all NBCCS and
control persons (WT, 𝑛 = 3; NBCCS, 𝑛 = 8) (PTCH1−,
𝑛 = 2; PTCH1+, 𝑛 = 6). NBCCS patients were separately ana-
lyzed according to the different types of PTCH1 mutation
(nonsense versus missense).
GS patients 1, 2, and 3 harbored nonsense independent
mutations in PTCH1; GS patients 4, 5, and 6 harbored
missense independent mutations in PTCH1. GS patients 7
and 8 carried PTCH1wild-type. GS patients 2, 3, and 5 carried
a PTCH1 mutation in the same extracellular loop 1, differing
from patients 1, 4, and 6 that harbored mutations in the
intracellular loop 3 and transmembranous domains 10 and 3,
respectively (Table 1).
SELDI-ToF mass spectrometry analysis was conducted
on cultured fibroblasts lysates and conditioned culture media
obtained from fibroblast cultures of the enrolled patients
and control populations. Controls were matched by age, sex,
and geographical region. The respective skin samples were
collected after clinical evaluation and review of the family
history.
2.3. Immunofluorescence Analysis. To evaluate Vimentin and
MMP1 expression in our cultures, cells were grown on
chamber-slides. After 72 hours, cells were washed with pho-
sphate buffer (PBS) and fixed with paraformaldehyde 4% for
10min.
To block nonspecific binding, cells were incubated with
0.5% Bovine SerumAlbumin, 5%Goat Serum for 15min, and
then incubated with primary antibodies: Monoclonal Mouse
Anti-Vimentin (clone Vim3B4 Dako, 1 : 100) and Mono-
clonal Mouse Anti-Matrix Metalloproteinases (MMP) 1
(clone 3B6 Santa Cruz, 1 : 100) for 1 hour at room temperature.
Subsequently, cells were incubated with secondary antibody
anti-mouse AlexaFluor 488 (1 : 100 dilution) and AlexaFluor
546 (1 : 100 dilution) (Molecular Probe Inc., Eugene, OR) for
45min at room temperature. Fluorescent specimens were
analyzed by a confocal scanning laser microscope Nikon A1
(Nikon Instruments, Japan).
2.4. Sample Preparation: Total Cell Lysates and Conditioned
Media. Samples were obtained from cultured fibroblast pre-
viously isolated by healthy skin biopsies of allNBCCSpatients
and control individuals, from sun-protected healthy areas.
Primary dermal fibroblasts were isolated by explant and
cultured as previously described [12]. Experiments were per-
formed using cells at passage 6. At subconfluency, the growth
medium was changed with quiescent medium (serum free)
24 h before collection of conditioned media (CM) and cell
lysates.
TheCM collected was filtrated (0.2𝜇m) and concentrated
by Amicon Ultra 3 K (Millipore, USA) according to the man-
ufacturer’s recommendations.
The fibroblasts were washed with phosphate buffer pH
7.4 (PBS, Gibco, USA) and lysated with 300 𝜇L of lysis buffer
(7M urea, 2M thiourea, 3% CHAPS, 40mMTRIS pH 8.3, 1%
ampholytes pH 3–10) plus a cocktail of proteinase inhibitors
(Roche, Switzerland). The samples were freeze/thawed and
sonicated. The cell proteins were obtained through centrifu-
gation at 15000×g for 15min to remove insoluble debris.
The total protein in cell lysates and in CM was quantified
using the classical Bradford method (Bio-Rad Laboratories,
Inc., Hercules, CA, USA) according to the manufacturer’s
instructions [13]. There were no relevant differences in pro-
tein concentration between any of the cell groups.
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Table 1: Genetic and clinical characteristics of NBCCS affected patients.
Pts Gene Exon Sequenceinvolved Domain Mutation BCC
Odontogenic
ceratocystis Pits
Falx cerebri
calcification
Skeletal
abnormalities
NBCCS
affected
relatives
1 PTCH 14
c.1987C>T
[p.Q663X] Intracellularloop 3 Stop Yes Yes None None Yes Yes
2 PTCH 9
c.1237C>T ht
p.Q413X Extracellularloop 1 Stop Yes Yes Yes Yes Yes Yes
3 PTCH 4 c.654 +2T>A
Extracellular
loop 1 Splicing Yes Yes None None None Yes
4 PTCH 6 c.931dupA
Extracellular
loop 1 Frameshift Yes Yes None None None Yes
5 PTCH 19
c.3277G>A;
p.G1093R Transmembrane10 Missense Yes Yes Yes Yes None Yes
6 PTCH 10 c.1348 −2A>Ght
Transmembrane
3 Splicing None Yes None None None
Yes
7 PTCH — Wilde type — — Yes None None None None None
8 PTCH — Wilde type — — Yes Yes None None Yes None
Legend BCC: basal cell carcinoma; NBCCS: nevoid basal cell carcinoma syndrome.
2.5. SELDI-ToF-MS Protein Profiling. Lysate and conditioned
culture medium samples were analyzed with SELDI-ToF-MS,
with the purpose to investigate the protein profile in both the
low (2–30 kDa) and the high (30–100 kDa)molecular weights
(MW). In a preliminary study, in order to set up the exper-
imental conditions, pooled samples were loaded onto two
different types of ProteinChip Arrays (Bio-Rad Laboratories
Inc., Hercules, CA, USA): CM10 (weak cation-exchanger)
and IMAC30-Cu (Immobilized Metal Affinity Capture sur-
face preactivated with copper). The IMAC30-Cu array gave
the higher number of peaks detected and the higher total
signal intensity compared to CM10, so this array was used
in the main study. After preequilibration, 90𝜇L of binding
buffer (0.1M sodium phosphate, 0.5M sodium chloride, pH
7, Bio-Rad Laboratories Inc., Hercules, CA, USA) was mixed
with 20𝜇L of fibroblasts conditioned medium or 5 𝜇L of
cell lysates to obtain a 0.3 𝜇g/𝜇L final protein concentration
that was then loaded onto IMAC30-Cu ProteinChip Array
spot surfaces, according to the manufacturer protocols. After
45min incubation at room temperature with shaking, the
unbound proteinswere removed by threewashing steps using
200𝜇L of the same binding buffer. Finally, 1 𝜇L of saturated
sinapinic acid solution in 0.5% trifluoroacetic acid and 50%
acetonitrile (Sigma-Aldrich, St. Louis,MO, USA) was applied
to each spot twice, allowing the surface to dry between each
application.
2.6. Data Acquisition. The ProteinChip Arrays were ana-
lyzed with a SELDI-ToF-MS reader (Series 4000, Bio-Rad
Laboratories Inc., Hercules, CA, USA), by protocols opti-
mized for low (1.5–30 kDa) and high (30–150 kDa) molecular
weight (MW) ranges. Mass spectra were acquired using low
(3500 nJ) and high (7500 nJ) laser energies averaging 901 laser
shots onto the spot surface.
The “All-in-one protein standard II” (Bio-Rad Labora-
tories Inc., Hercules, CA, USA) was used to obtain protein
standard spectra for mass accuracy calibration.
2.7. Statistical Analysis. Statistical analysis was performed
using the ProteinChip Data Manager 3.0 software (Bio-Rad
Laboratories Inc., Hercules, CA, USA) as previously reported
[10]. Briefly, spectra were preprocessed performing mass
calibration, baseline subtraction, alignment, and total ion
current (TIC) normalization. Supervised clustering was done
with the following settings: 5 times signal-to-noise (S/N)
ratio and 20% min peak threshold in the first pass for peaks
identification, and 2 times S/N ratio on the second pass
for cluster completion. Finally, cluster peak intensities were
compared by Mann-Whitney 𝑈 test. A 𝑃 value less than 0.05
was accepted as statistically significant.
3. Results
3.1. Isolation of Primary Fibroblastic Population from Human
Skin Tissue. Fibroblasts were extracted from eleven human
skin samples obtained from surgical resection. The skin was
dissociated, and various cell types were separated to obtain
populations of fibroblasts. The cultures reached confluence
after two weeks and were stored in −80∘C at cell passage
6.
3.2. MMP1 and Vimentin Immunofluorescence Analysis. The
cultured primary cells showed typical fibroblast-like features,
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Figure 1: Immunostaining characteristics of primary fibroblastic
cells. All primary fibroblasts isolated from skin biopsies of PTCH1
gene-carrier patients with Gorlin syndrome strongly expressed
fibroblastic marker Vimentin (magnification: ×20; ruler: 10 𝜇m).
with spindle-like shapes and elongated projections. Perform-
ing immunofluorescence analysis of vimentin expression, we
confirm the fibroblast nature of isolated cells (Figure 1).
Moreover, we detected a strongly MMP1 overexpression
in PTCH1mutated fibroblasts obtained fromNBCCS patients
with respect to healthy donors (Figure 2).
3.3. Protein Profiling of Total Cell Lysates and Conditioned
Media. We compared the proteomic expression profiles of 11
fibroblasts conditioned cultures media and total cell lysates
(WT, 𝑛 = 3; PTCH1− NBCCS, 𝑛 = 2; PTCH1+ NBCCS,
𝑛 = 6), obtained with IMAC30 Cu pretreated ProteinChip
arrays.
The statistical analysis of peak intensities of total cell
lysates of fibroblast NBCCS patients and control individu-
als revealed an elevated number of differentially expres-
sed protein masses (56 in total: 35 in the range 1.5–30 kDa
and 21 in the range 30–150 kDa (see Table 1 provided
as Supplementary Material available online at http://dx.doi
.org/10.1155/2013/794028).
In contrast, only 11 differentially expressed peaks were
detected in the comparison between patients and con-
trols fibroblast conditioned media. Peaks, listed in Table 2,
(a)
(b)
Figure 2: Immunostaining characteristics of primary fibroblastic
cells. All primary PTCH1+ fibroblasts strongly expressed fibroblastic
marker MMP1 (magnification: ×20; ruler: 10 𝜇m).
Table 2: Comparison of peak intensities between NBCCS and
controls individuals fibroblast conditioned media for IMAC30-Cu.
For each cluster peak comparison, the 𝑃 value was <0.05.
(M/Z) NBCCS patients Control individuals
Intensity (mean ± SD) Intensity (mean ± SD)
5877 77.87 ± 29.40 136.27 ± 1.79
5983 13.98 ± 3.25 20.31 ± 1.59
11753 504.65 ± 214.86 911.32 ± 60.29
11858 46.33 ± 18.33 77.45 ± 5.24
11964 68.14 ± 27.70 125.64 ± 4.77
12369 9.80 ± 2.97 16.56 ± 3.18
16274 0.82 ± 1.22 4.92 ± 4.55
21811 7.62 ± 2.08 11.36 ± 1.40
28901 0.48 ± 0.27 1.34 ± 0.86
29145 0.52 ± 0.23 1.24 ± 0.67
33333 6.92 ± 1.52 3.34 ± 0.65
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Figure 3: Representative spectra obtained by SELDI-ToF-MS analysis concerning the statistically significant peaks detected with IMAC30-
Cu listed in Table 2. The peaks of interest are highlighted in rectangles and their m/z values are reported above. (NBCCS: nevoid basal cell
carcinoma syndrome Patients; CTRL: control subjects).
ranged from 5.8 kDa to 33.3 kDa and were all overex-
pressed in control individuals but the peak with m/z of
33.3 kDa. Figure 3 shows a typical mass protein profile in
NBCCS patients and control individuals for all the peaks of
Table 2.
The peak intensities were further analyzed in the PTCH1+
total lysates and conditioned media: 6 and 7; protein peaks
were statistically different (𝑃 < 0.05), comparing PTCH1+
nonsense and missense mutations, respectively (Table 3).
For the conditioned cultured media, all protein peaks are
overexpressed in PTCH1+ stopmutation, conversely all peaks
are overexpressed for the PTCH1+ missense for the total
fibroblast lysates. Interestingly, none of these peaks is in
common with those differently expressed in the comparison
between NBCCS patients and control individuals, so they are
probably specific of different type of mutation.
It was also possible to find differences in protein expres-
sion comparingNBCCSpatients according to their aggressive
or not aggressive phenotype. Table 4 shows 7 statistically
different peaks for both fibroblast and conditioned culture
media. In this comparison, five peaks (m/z 6190, 16274,
16387, 34368, and 44306) are overexpressed while two under-
expressed (m/z 8575, 13558) while only one (m/z 35968) in
NBCCS not aggressive phenotype for culture media, and
lysates, respectively. Also these peaks are not in common
with those discovered in the previous comparison, indicating
their specific role in determining a different phenotype of the
disease.
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Table 3: Comparison of peak intensities between PTCH1+missense
and PTCH1+ nonsense fibroblast conditioned media and lysates for
IMAC30-Cu. For each cluster peak comparison, the 𝑃 value was
<0.05.
(M/Z) PTCH1+missense PTCH1+ nonsense
Intensity (mean ± SD) Intensity (mean ± SD)
Fibroblast cultured media
3183 4.90 ± 2.23 15.06 ± 6.99
7327 7.05 ± 1.95 12.04 ± 1.99
7404 5.70 ± 1.78 10.40 ± 1.96
14607 9.75 ± 2.22 24.42 ± 10.18
14656 18.68 ± 7.40 32.33 ± 2.86
14868 3.79 ± 1.14 6.83 ± 0.15
14938 5.35 ± 1.99 7.86 ± 0.16
Fibroblast lysates
5665 17.98 ± 5.93 6.89 ± 1.31
11326 84.86 ± 33.54 20.49 ± 13.64
11365 38.62 ± 14.78 9.36 ± 6.17
11531 11.80 ± 3.52 3.52 ± 2.20
30482 0.21 ± 0.06 0.08 ± 0.06
107051 0.06 ± 0.02 0.09 ± 0.01
4. Discussion
The investigation of different cohorts of healthy individuals
and patients carrying different germ-line PTCH1 mutations
through the comparison of proteomic profiles supports the
hypothesis that epithelial oncogenesis could be induced by
a dermal-epidermal cross-talk based on proteins that are
directly produced by dermal fibroblasts. This mechanism is
mainly involved in the development of multiple early onset
BCCs arising on non-sun-damaged skin, which is not usually
affected in nonsyndromic patients.
SELDI-ToF-MS analysis is a proteomic technology rega-
rded as one of the most powerful tools useful to investigate
a differential expression profile in the low (2–30 kDa) and
the high (30–100 kDa)molecularweights (MW).Ourmethod
represents a novel approach based on the study of condi-
tioned media through the extended proteomic analysis. In
fact, the application of SELDI-ToF technique had so far been
limited to cell lysates for which the huge quantity of proteins
represents a consistent obstacle to the clear identification of
specific protein clusters specifically associated to PTCH1+/−
fibroblasts and/or NBCCS patients with aggressive/mild clin-
ical behavior.
In our study we analyzed by the SELDI-ToF technique
samples of fibroblasts conditioned media from 8GS patients
(6 gene carriers of PTCH1 mutations and 2 PTCH1 WT)
and 3 healthy controls, obtaining peculiar clusters of protein
peaks for IMAC30-Cu and 95 for CM10 ProteinChip Arrays,
respectively.
It is known that development of BCC cells depends on the
existence of their carcinoma associated fibroblasts (CAF) [14,
15]. A previous study on the whole genome expression in GS
and healthy controls disclosed a genomic signature including
Table 4: Comparison of peak intensities betweenNBCCS aggressive
and NBCCS nonaggressive fibroblast conditionedmedia and lysates
for IMAC30-Cu. For each cluster peak comparison, the 𝑃 value was
<0.05.
(M/Z) NBCCS aggressive
NBCCS not
aggressive
Intensity (mean ± SD) Intensity (mean ± SD)
Fibroblast cultured media
6190 11.92 ± 5.27 31.35 ± 10.26
8575 26.79 ± 1.03 13.82 ± 10.13
13558 7.86 ± 1.24 5.62 ± 1.27
16274 0.05 ± 0.13 1.59 ± 1.39
16387 0.38 ± 0.11 1.18 ± 0.56
34368 4.17 ± 0.93 6.95 ± 1.03
44306 5.38 ± 1.54 1.55 ± 1.13
Fibroblast lysates
1423 24.57 ± 4.36 17.18 ± 2.87
1503 86.94 ± 41.74 35.49 ± 18.67
1526 133.27 ± 49.21 64.94 ± 22.44
1751 39.93 ± 17.78 16.84 ± 6.95
1771 65.06 ± 29.51 27.25 ± 10.33
35968 0.26 ± 0.03 0.53 ± 0.28
53535 1.50 ± 0.19 1.13 ± 0.14
several genes known for their association with tumor growth
and invasiveness [16]. The authors highlighted that the
PTCH1+ genotype of fibroblasts obtained from healthy skin
of NBCCS patients is similar to BCCs’ associated fibroblasts.
In fact, NBCCS fibroblasts overexpressed mRNAs encoding
protumoral factors such as Matrix Metalloproteinases 1 and
3 and tenascin C, proproliferative diffusible factors such as
fibroblast growth factor 7, and the stromal cell-derived factor
1 alpha.
However, in contrast toValin et al. [16]whodescribed that
missense or nonsense mutations of PTCH1 have overall very
similar consequences on the transcriptome of dermal fibro-
blasts, we detected characteristic protein peaks of the con-
ditioned media discriminating between these two PTCH1
mutation patients groups. There is still no evidence concern-
ing PTCH1 associated transcriptome for nonsense PTCH1
mutations, but we can speculate that such mutations codify
for decay mRNA linked to soluble cytosolic PTCH1 variants,
instead of transmembranous proteins. The absence of this
transmembranous protein receptor can be related to the con-
stitutional activation of SHH pathway, which increases pro-
tein synthesis and secretion. On the contrary, missense
PTCH1 mutations may lead to the production of defective
receptors that may explain the reduced synthetic ability of
WT fibroblasts.
The protein peaks identified in conditioned media of
PTCH1+ fibroblasts may include peptides or small proteins
with low abundance, which can scarcely be revealed using
lysate cells, in which proteins are present in large quantity.
However, the main SELDI-ToF limits are that it does not
allow protein detection of higher molecular weight proteins
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and does not consent peaks identification such as the pos-
tulated growth factors or matrix proteins. A specific analysis
through the TagIdent tool with pI and mass information
was conducted, in order to obtain matching information
for each protein peak. However, an excess of meaningful
matching proteins was found, indicating that the functions of
these putative uncharacterized proteins are undefined. At this
regard, we have preliminary data showing thatMMP1 is over-
expressed in the PTCH1mutated fibroblasts, confirming that
there is a relationship between PTCH1mutation and MMP1-
related ability to induce neoplastic transformation of the
epithelial cells. In addition, MMP1 can be a novel target for
experimental tailored therapy of malignancies in the setting
of NBCCS. A future characterization of these peculiar pro-
teomic signature can be useful for the clinical, prognostic, and
therapeutic evaluation of those patients.
Patients affected from multiple BCCs that cannot or do
not want to undergo surgery can benefit from the treatment
with Vismodegib, a systemic drug that has provided good
response rates in the trials [17]. However, effective response
rates are limited by drug resistance mechanisms, a common
limit which is observed in most molecular targeted therapies.
In the case of Vismodegib, about one-third of BCCs in
advanced stage usually show a positive drug response in the
very beginning, but continuative administration leads to sig-
nificant secondary resistance [18]. Resistance mechanisms
have been described for both sporadic BCC patients and
GS patients who carry PTCH1 germline mutations; in the
latter, it has been hypothesized that BCCs in advanced stage
would have higher chances of developing resistantmutations.
This might be due to both higher mutation rates and/or the
presence of an increased number of tumor cells [7]. A further
explanationmight be linked to the initial amplified resistance
and ability to develop drug independent growth potential that
characterizes more aggressive BCCs.
Each target therapy has its own resistance mechanisms,
which are due to acquired or initially present secondary mut-
ations that affect genes involved in the target pathways. Their
occurrence can be prevented through the introduction of
multitarget inhibitors that help avoid resistance mechanisms,
finally leading to an increased disease-free survival. For both
BCCs and medulloblastomas in GS, determining specific
proteomic patterns in individuals with particularly aggressive
phenotypes might lead to both experimental approaches and
clinical trials on multiple smoothed therapies. Those should
be pointed towards the simultaneous inhibition of several
molecular targets involved in the pathogenesis and clinical
progression of syndromic tumors.
In this study, we used SELDI-ToF-MS analysis to eval-
uate the protein profiles of PTCH1 and control samples of
fibroblast conditioned media. Statistical analysis of differen-
tially expressed protein peaks has given the possibility to
define algorithms, which could distinguish between NBCCS
patients and control individuals.
Our data prove that the SELDI-ToF-MS technology is
capable to detect a set of protein peaks as candidate bio-
markers, rapidly and with high throughput. protein peaks
profiling provided a better understanding of the complex
skin cancer microenvironment and could be useful to select
patients at risk to develop multiple and aggressive BCCs
and/or other NBCCS-associated malignancies. These are the
patients which could benefit from a systemic drug approach
and/or require specific clinical and instrumental followup.
However, further studies, involving PTCH1+ fibroblasts and
keratinocytes cocoltures are required to recognize and cor-
roborate the revealed protein peaks.
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